Intercept Pharmaceuticals has voluntarily pulled Ocaliva (obeticholic acid) from the US market following a request from the ...

Intercept Pharmaceuticals has voluntarily removed Ocaliva from the United States market for the treatment of primary biliary ...

OCALIVA received FDA accelerated approval in 2016 for the treatment of PBC in adults with an inadequate response to or intolerance of ursodeoxycholic acid (UDCA). Since then, OCALIVA has played a ...

Ocaliva, approved for primary biliary cholangitis, faced FDA warnings and restrictions after postmarket data showed higher ...

Ahead of New York Fashion Week, Gilead Sciences is strutting its marketing stuff to raise awareness of primary biliary ...

Ocaliva won accelerated approval for primary biliary cholangitis in 2016, which the FDA refused to upgrade to full approval ...

Intercept Pharmaceuticals has pulled obeticholic acid (Ocaliva) from the U.S. market as a treatment for primary biliary ...

Intercept Pharmaceuticals withdraws Ocaliva from the U.S. market following FDA concerns over safety and effectiveness for ...

Alfasigma's $800 million buyout of Intercept Pharma two years ago is starting to look like a poor bet, as its only approved ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — Healio spoke with James L. Boyer, MD, about phase 3 findings from the RESPONSE trial and the ELATIVE ...

A primary biliary cholangitis (PBC) diagnosis can be life-changing. For many, it’s an emotional journey filled with questions, uncertainties and a need to redefine what life looks like with a chronic ...

The Business Research Company's Primary Biliary Cholangitis Therapeutics Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 Get 30% Off All Global Market Reports With Code ...